国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2013年
2期
183-186
,共4页
支原体肺炎%小儿%孟鲁司特钠%阿奇霉素
支原體肺炎%小兒%孟魯司特鈉%阿奇黴素
지원체폐염%소인%맹로사특납%아기매소
Mycoplasma pneumonia%Pediatric%Montelukast sodium%Azithromycin
目的 探讨孟鲁司特钠联合阿奇霉素治疗小儿支原体肺炎(MP)的临床应用效果.方法 将82例MP患儿随机分为观察组和对照组各41例,对照组在常规治疗的基础上口服阿奇霉素,观察组在对照组的基础上加用孟鲁司特钠咀嚼片口服.比较两组患儿的体温恢复时间、咳嗽消失时间、喘息消失时间以及随访6个月内发生哮喘的情况.结果 观察组与对照组的体温恢复时间、咳嗽消失时间、喘息消失时间分别为(3.8±1.1)d、(21.4±3.4)d、(8.1±1.7)d和(3.5±1.5)d、(8.1±2.5)d、(6.0±1.5)d;观察组与对照组患儿支原体肺炎感染后继发哮喘的发病率分别为9.76％和39.02％;观察组与孟鲁司特钠相关的可疑不良反应1例,表现为皮疹,未经停药后自行缓解,未见其他明显不良反应.结论 孟鲁司特钠联合阿奇霉素治疗小儿MP具有较好的临床效果,不但能明显改善患儿的临床症状、体征,且复发率低、并发症少,值得临床推广应用.
目的 探討孟魯司特鈉聯閤阿奇黴素治療小兒支原體肺炎(MP)的臨床應用效果.方法 將82例MP患兒隨機分為觀察組和對照組各41例,對照組在常規治療的基礎上口服阿奇黴素,觀察組在對照組的基礎上加用孟魯司特鈉咀嚼片口服.比較兩組患兒的體溫恢複時間、咳嗽消失時間、喘息消失時間以及隨訪6箇月內髮生哮喘的情況.結果 觀察組與對照組的體溫恢複時間、咳嗽消失時間、喘息消失時間分彆為(3.8±1.1)d、(21.4±3.4)d、(8.1±1.7)d和(3.5±1.5)d、(8.1±2.5)d、(6.0±1.5)d;觀察組與對照組患兒支原體肺炎感染後繼髮哮喘的髮病率分彆為9.76％和39.02％;觀察組與孟魯司特鈉相關的可疑不良反應1例,錶現為皮疹,未經停藥後自行緩解,未見其他明顯不良反應.結論 孟魯司特鈉聯閤阿奇黴素治療小兒MP具有較好的臨床效果,不但能明顯改善患兒的臨床癥狀、體徵,且複髮率低、併髮癥少,值得臨床推廣應用.
목적 탐토맹로사특납연합아기매소치료소인지원체폐염(MP)적림상응용효과.방법 장82례MP환인수궤분위관찰조화대조조각41례,대조조재상규치료적기출상구복아기매소,관찰조재대조조적기출상가용맹로사특납저작편구복.비교량조환인적체온회복시간、해수소실시간、천식소실시간이급수방6개월내발생효천적정황.결과 관찰조여대조조적체온회복시간、해수소실시간、천식소실시간분별위(3.8±1.1)d、(21.4±3.4)d、(8.1±1.7)d화(3.5±1.5)d、(8.1±2.5)d、(6.0±1.5)d;관찰조여대조조환인지원체폐염감염후계발효천적발병솔분별위9.76％화39.02％;관찰조여맹로사특납상관적가의불량반응1례,표현위피진,미경정약후자행완해,미견기타명현불량반응.결론 맹로사특납연합아기매소치료소인MP구유교호적림상효과,불단능명현개선환인적림상증상、체정,차복발솔저、병발증소,치득림상추엄응용.
Objective To investigate the clinical effect of montelukast sodium combined with the azithromycin treatment of mycoplasma pneumonia(MP).Methods 82 cases of MP children were randomly divided into observation group and control group,41 cases in each group,the control group was treated by the azithromycin on the basis of the conventional treatment,the observation group was treated by montelukast sodium on the basis of the treatment for control group,and then compared the children' s body temperature recovery time.cough disappeared time,wheezing disappeared time,and the asthma follow-up occurred within 6 months between the tw0 groups.Results The body temperature recovery time of the observation group and the control group were (3.8 ± 1.1) d and (3.5 ± 1.5) d respectively,the differences were not statistically significant between the two groups (P＞0.05).The coughing and wheezing disappeared time in the observation group and the control groupwere( 21.4 ± 3.4 ) d,(8.1 ± 2.5) d and( 8.1 ± 1.7) d,( 6.0 ± 1.5 ) d,the difFerences were statistically significant between the two groups ( P＜0.05 ).Disease incidence of the mycoplasma pneumomae infection secondary to asthma in the observation group and the control group were 39.02% and 9.76%.the differences were statistically significant between the two groups ( P＜O.01 ).One case of suspected adverse reactions associated with montelukast sodium in the observation group.the incidence of 2.44%.expressed as rash,without spontaneous remission after discontinuation.There were no other significant adverse reactions occurred.Conclusion Montelukast sodium azithromycin treatment for children with MP has better clinical effects,not only can significantly improve the clinical symptoms and signs of the children,but also can reduce the recurrence rate,with fewer complications,which is worthy of clinical application.
